Your browser doesn't support javascript.
loading
Post COVID-19 condition of the Omicron variant of SARS-CoV-2.
Morioka, S; Tsuzuki, Shinya; Suzuki, M; Terada, M; Akashi, M; Osanai, Y; Kuge, C; Sanada, M; Tanaka, K; Maruki, T; Takahashi, K; Saito, S; Hayakawa, K; Teruya, K; Hojo, M; Ohmagari, N.
Afiliación
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hosp
  • Tsuzuki S; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Suzuki M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Akashi M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Osanai Y; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Kuge C; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Sanada M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Tanaka K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Maruki T; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Takahashi K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Hayakawa K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Teruya K; AIDS Clinical Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Hojo M; Division of Respiratory Medicine, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
J Infect Chemother ; 28(11): 1546-1551, 2022 11.
Article en En | MEDLINE | ID: mdl-35963600
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article